This recombinant monoclonal antibody is developed as a research-grade biosimilar to Spesolimab, targeting IL1RL2 (Interleukin-1 Receptor-Like 2), also known as IL-36R. IL1RL2 serves as the receptor for IL-36 cytokines, which are members of the interleukin-1 superfamily that play critical roles in innate immune responses and inflammatory signaling. Upon ligand binding, IL1RL2 activates downstream pathways including NF-κB and MAPK, leading to the production of pro-inflammatory mediators. Dysregulated IL-36/IL1RL2 signaling has been implicated in various autoinflammatory and autoimmune conditions, particularly generalized pustular psoriasis (GPP), palmoplantar pustulosis, and other neutrophilic dermatoses.
Spesolimab is a humanized IgG1 monoclonal antibody that selectively blocks IL1RL2, preventing IL-36 cytokine binding and subsequent inflammatory cascade activation. This biosimilar antibody provides researchers with a valuable tool for investigating IL-36 receptor biology, studying inflammatory disease mechanisms, and exploring therapeutic interventions in IL-36-driven pathological conditions. It enables detailed examination of IL1RL2-mediated signaling pathways and immune cell activation in various experimental models.
Email: support@cusabio.com
Distributors Worldwide